Ace Management Global Ltd. lessened its position in Masimo Co. (NASDAQ:MASI - Free Report) by 95.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 47,694 shares of the medical equipment provider's stock after selling 917,810 shares during the quarter. Masimo makes up about 100.0% of Ace Management Global Ltd.'s investment portfolio, making the stock its largest holding. Ace Management Global Ltd. owned about 0.09% of Masimo worth $7,884,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Jones Financial Companies Lllp bought a new position in Masimo during the 4th quarter valued at approximately $27,000. UMB Bank n.a. increased its position in Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after buying an additional 123 shares in the last quarter. Trust Co. of Vermont bought a new position in Masimo during the 4th quarter valued at approximately $33,000. Blue Trust Inc. increased its position in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 71 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.
Wall Street Analyst Weigh In
MASI has been the subject of a number of analyst reports. Stifel Nicolaus reaffirmed a "buy" rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Wells Fargo & Company lifted their target price on Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Piper Sandler lifted their target price on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a report on Wednesday, February 26th. Finally, Raymond James lifted their target price on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a report on Friday, December 27th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Masimo currently has a consensus rating of "Moderate Buy" and an average price target of $194.80.
Read Our Latest Analysis on MASI
Masimo Stock Performance
Shares of MASI traded down $1.09 during trading hours on Friday, hitting $174.52. The stock had a trading volume of 630,748 shares, compared to its average volume of 620,916. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The firm has a market capitalization of $9.42 billion, a PE ratio of 120.36 and a beta of 1.04. The stock has a fifty day moving average price of $174.95 and a 200 day moving average price of $156.02.
Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Analysts anticipate that Masimo Co. will post 4.1 EPS for the current year.
About Masimo
(
Free Report)
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Read More
Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
